The serum low-density lipoprotein cholesterol test interpretation 
 
 
The national health and family planning commission of the People's Republic of China 

    One, the standards of the background and significance
 
    Cardiovascular disease has become the first cause of death of the rural and urban population. Monitoring found that the increased incidence of ischemic cerebral apoplexy, predicted based on the disease of atherosclerosis ischemic cardio-cerebrovascular diseases, including coronary heart disease and ischemic stroke rates are rising. Epidemiology and evidence-based medicine studies have shown that serum low-density Lipoprotein Cholesterol, Low Density Lipoprotein Cholesterol, LDL - C) rise is one of the independent risk factors for coronary heart disease and ischemic stroke. Therefore, the prevention of ischemic disease of heart head blood-vessel, early diagnosis, to emphasis on the prevention and treatment of dyslipidemia.
 
    Second, the main technical content
 
    Serum low-density Lipoprotein Cholesterol (Low Density Lipoprotein Cholesterol, LDL - C) is clinically important for prevention and control of dyslipidemia testing project, it is mainly used for caused by diabetes, high blood pressure, high Cholesterol atherosclerosis risk assessment of sexual disease of heart head blood-vessel, individualized health care and treatment monitoring. Popular both at home and abroad to LDL - C as lipid-lowering treatment of patients with cardiovascular disease is the most important targets. According to the patient's level of LDL - C combining with the history, on the one hand, evaluation of the patient's level of risk, on the other hand, whether the patient should adopt medical intervention and intervention, but also cut the level of LDL - C as the target of treatment.
 
    Division of LDL - C USES the fixed point of tangency, LDL - C < 3.37 tendency for appropriate level L, LDL - C in (3.37 ~ 4.12) between the tendency for L to edge higher, LDL - C or greater tendency for 4.14 / L to rise. Dyslipidemia treatment is the most main purpose is for the sake of prevention and treatment of coronary heart disease, so should be based on whether the existing dangerous disease such as coronary heart disease or coronary heart disease and presence of cardiovascular risk factors, combined with the comprehensive evaluation on the blood lipid level, to decide the goal of the treatment and blood lipid levels.
 
    Because of dyslipidemia has close relationship with diet and lifestyle, so diet therapy and improve the way of life is the foundation of dyslipidemia treatment measures. In determining the lipid adjusting treatment with drugs, and some need a comprehensive understanding of patients with coronary heart disease and risk factors associated with. In lipid adjusting treatment, should will reduce LDL - C as a priority. Clinically in tiaozhi therapy and decided to start the drug to reach the target, need to consider whether patients with coexist and other major risk factors for coronary heart disease (that is, the risk factors other than the LDL - C). Analysis of the major risk factors for coronary heart disease (CHD) will help to judge the degree of danger of suffering from coronary heart disease (CHD), thus decided to lower the LDL - C target. Different risk groups, began to drug treatment of LDL - C level and to achieve the target value of LDL - C are quite different. Therefore, LDL - C determination is extremely important.
 
 
Relevant link: about release the prostate specific antigen to detect prostate cancer clinical application and so on four recommended industry standards of health notices